Eric T. Ong

Eric T. Ong is an Intellectual Property & Technology associate in O'Melveny & Myers' San Francisco office, focusing his practice on patent litigation, patent analysis, infringement cases, and IP counseling. His professional experience encompasses a broad range of intellectual property and technology disputes. Ong's scientific background includes prior work as a research scientist for Regeneron Pharmaceuticals, where he developed platform technologies to advance drug development, which informs his work in life sciences and biotechnology-related intellectual property. He also co-authored an article on the intellectual property implications of COVID-19 vaccine waivers.

While the provided case data includes one appearance on the plaintiff side, his practice description suggests he handles a wide array of matters, indicating he likely represents both plaintiffs and defendants in patent infringement disputes. Prior to joining O'Melveny, Ong practiced patent prosecution, patent litigation, and IP counseling at another global law firm.

No specific notable cases, trial verdicts, or significant settlements for Eric T. Ong could be reliably sourced through public web searches. Although he is registered to practice before the U.S. Patent & Trademark Office, his professional profile does not specifically highlight frequent appearances in PTAB or IPR proceedings.

Ong is admitted to practice in California and is registered with the U.S. Patent & Trademark Office. He earned his J.D., cum laude, from The University of California College of Law, San Francisco, and holds both an M.S.E. and B.S. in Chemical and Biomolecular Engineering from Johns Hopkins University.